Online inquiry

IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7143MR)

This product GTTS-WQ7143MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CTGF gene. The antibody can be applied in Hepatic fibrosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001901.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1490
UniProt ID P29279
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7143MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5223MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ1589MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ9265MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ8977MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ8347MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA hPAM4
GTTS-WQ7209MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ7100MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ1664MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACT-017
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW